NIH launched the Tissue Chip for Drug Screening program to develop 3-D human tissue chips containing bioengineered models that mimic human physiology. The aim is to use these chips to better predict the safety and effectiveness of candidate drugs. Scientists now are collaborating to combine the chips into an integrated system or human body-on-a-chip.
There are no open funding opportunities at this time.
These expired funding announcements include details on the application process, eligibility and timelines for the program:
RFA-TR-16-017: Microphysiological Systems (MPS) for Disease Modeling and Efficacy Testing (UG3/UH3)
RFA-TR-16-019: NIH-CASIS Coordinated Microphysiological Systems Program for Translational Research in Space (UG3/UH3)
PA-16-178: Limited Competition: Tissue Chips and Missing Organs (Admin Supp)
PA-16-173: Limited Competition: Tissue Chips for Rare Diseases (Admin Supp)
RFA-TR-16-006: Tissue Chip Testing Centers: Validating Microphysiological Systems (U24)
- Tissue Chip Specifications (Excel - 21KB)
- Confidential Disclosure Agreement (PDF - 27KB)
- Collaborative Research Agreement (PDF - 110KB)
RFA-RM-11-022: Integrated Microphysiological Systems for Drug Efficacy and Toxicity Testing in Human Health and Disease (UH2/UH3)
RFA-RM-12-001: Stem/Progenitor Cell-Derived Human Micro-Organs and -Tissues (U18)
NCATS acknowledges the following NIH Institutes for their contribution to this trans-NIH program: the Eunice Kennedy Shriver National Institute of Child Health and Human Development; the National Cancer Institute; the National Eye Institute; the National Heart, Lung, and Blood Institute; the National Institute of Allergy and Infectious Diseases; the National Institute of Arthritis and Musculoskeletal and Skin Diseases; the National Institute of Biomedical Imaging and Bioengineering; the National Institute of Dental and Craniofacial Research; the National Institute of Diabetes and Digestive and Kidney Diseases; the National Institute of Environmental Health Sciences; the National Institute of General Medical Sciences; the National Institute of Neurological Disorders and Stroke; the National Institute of Nursing Research; and the National Institute on Drug Abuse. NIH’s Common Fund and National Institute of Neurological Disorders and Stroke initially led trans-NIH efforts to establish the program.